Uterine fibroids are benign (non-cancerous) growths that form inside, outside or in the wall of the uterus. They are most often seen in women between the ages of 30-40 but can occur at any age. Uterine fibroids are the most common pelvic growth affecting around 20 percent of all women by age 59. Uterine fibroids are the leading cause of infertility.
Some common symptoms associated with uterine fibroids include heavy menstrual bleeding, painful periods, vaginal bleeding at times other than menstruation, anemia, pain in the abdomen or lower back, pain during sex, difficulty urinating or frequent urination, constipation, rectal pain or difficulty getting pregnant.
In collaboration with AbbVie, Neurocrine Biosciences has a novel, oral treatment approved by the U.S. FDA for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. AbbVie is responsible for all development, marketing and commercialization of the treatment.